2Miller KD, Sweeney CJ, Sledge GW, et al. Redefining the target: chemotherapeutics as antiangiogenics [J]. J Clin Oncol, 2001, 19: 1195-1206.
3Belotti D, Vergani V, Drudis T, et al. The microtubuleaffecting drug paclitaxel has antiangiogenic activity [J]. Clin Cancer Res, 1996, 2: 1843-1849.
4Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs [J]. Cancer Res, 2002, 62: 6938- 6943.
5Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis [J]. J Hematother Stem Cell Res. 2002. 11: 103-118.
6Grant DS, Williams TL, Zahaczewsky M, et al. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere) [J]. Int J Cancer, 2003, 104: 121-129.
7Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly [J]. Anti Cancer Drugs 2003, 14: 13-19.
8Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J]. N Engl J Med, 2004, 350: 1713-1721.
9Wang JP, Kozo T, Tsuneji N, et al. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol [J]. Int J Pharm, 2003, 251: 13-21.
10Wang JP, Maitani Y, Takayama K. Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid [J]. J Pharm Sci, 2002, 91: 1128-1134.
1Deorah S, Lynch C F, Sibenaller Z A. Trends in braincancer incidence and survival in the United States:Surveillance, Epidemiology, and End Results Program,1973 to 2001 [J], Neurosurgery Focus, 2006, 20(4): El.
2Wang J,Goh B, Lu W, et al. In vitro cytotoxicity ofstealth liposomes coencapsulating doxorubicin andverapamil on doxorubicin-resistant tumor cells [J]. BiolPharm Bull,2005,28(5): 822-828.
3Lassoued W,Murphy D, Tsai J, et al. Effect of vegf andvegf trap on vascular endothelial cell signaling in tumors[J]. Cancer Biol Ther,2010,10(12): 1326-1333.
4Gallagher E J, Alikhani N,Tobin-Hess A, et al. Insulinreceptor phosphorylation by endogenous insulin or theinsulin analog AspBlO promotes mammary tumor growthindependent of the IGF-I receptor [J]. Diabetes,2013,62(10): 3553-3560.
5Pockaj B A, Basu G D, PathangeyL B, et al.ReducedT-cell and dendriticcell function is related tocyclooxygenase-2 over-expression and prostaglandin E2secretion in patients with breast cancer [J]. Ann SurgOncol, 2004,11(3): 328-339.
